Danaher Corporation is a global manufacturer and marketer of diverse products and services across the Biotechnology, Life Sciences, and Diagnostics segments, serving professional, medical, and industrial sectors. The company provides bioprocessing technologies, life science instruments, and diagnostic tools, positioning itself as a significant player in the scientific and medical industries within the Healthcare sector.
In its recent quarterly performance, Danaher has shown a mixed pattern of EPS beats and misses against analyst estimates. For Q4 2025, the company reported an actual EPS of $2.23, exceeding the estimate of $2.17, and revenue of $6.84 billion against an estimate of $6.87 billion. The prior quarter, Q3 2025, saw an actual EPS of $1.89 against an estimate of $1.72, with revenue at $6.05 billion. However, Q2 2025 reported an actual EPS of $1.80 against an estimate of $1.64, and Q1 2025 reported an actual EPS of $1.88 against an estimate of $1.64. Revenue for Q1 2025 was $5.74 billion, exceeding the estimate of $5.74 billion, while Q2 2025 revenue was $5.94 billion against an estimate of $5.94 billion.
Danaher's historical streak analysis reveals a pattern of generally exceeding EPS estimates in recent quarters, with Q4 2024 being a slight miss ($2.14 actual vs $2.16 estimate). The company has demonstrated consistent revenue generation, with Q4 2025 revenue slightly missing estimates but still showing substantial top-line figures. The trajectory indicates a stable performance, with the company often delivering results that align with or slightly surpass analyst expectations.
Recent news indicates that Danaher's proposed acquisition of Masimo is facing shareholder scrutiny and potential legal investigations, which could impact the transaction's timeline. Additionally, some analysis suggests Danaher's current valuation may be below its fair value estimate, with recent share price declines prompting a focus on intrinsic value. Evercore ISI has lowered its price target to $225 while maintaining an Outperform rating, highlighting the importance of continued core revenue growth and margin performance.
Moving forward, investors will be closely watching the outcome of the Masimo acquisition shareholder vote and any related legal developments. Key will be Danaher's ability to demonstrate continued core revenue growth and maintain strong operating margins, as highlighted by Evercore ISI's analysis. Investors should also monitor how the company's valuation evolves relative to its intrinsic value in the coming quarters.
